Renalytix AI plc (LSE:RENX) — Market Cap & Net Worth
Market Cap & Net Worth: Renalytix AI plc (RENX)
Renalytix AI plc (LSE:RENX) has a market capitalization of $332.33K (GBX2.73 Billion) as of September 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31198 globally and #978 in its home market, demonstrating a 11.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Renalytix AI plc's stock price GBX6.25 by its total outstanding shares 437018680 (437.02 Million). Also see how large is Renalytix AI plc's balance sheet for a full breakdown of the balance sheet.
Renalytix AI plc Market Cap History: 2018 to 2026
Renalytix AI plc's market capitalization history from 2018 to 2026. Data shows change from $6.51 Million to $332.33K (-31.30% CAGR). Also see RENX cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Renalytix AI plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$912.31 Million | 0.04% | #260 of 722 |
Weight: Renalytix AI plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Renalytix AI plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Renalytix AI plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check RENX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.10x
Renalytix AI plc's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $6.51 Million | $64.45 Billion | $7.23 Billion | 0.00x | 0.00x |
| 2020 | $25.92 Million | $58.31 Billion | -$9.84 Million | 0.00x | N/A |
| 2021 | $33.50 Million | $1.49 Million | -$34.73 Million | 22.47x | N/A |
| 2022 | $3.86 Million | $2.97 Million | -$45.28 Million | 1.30x | N/A |
| 2023 | $824.17K | $59.60 Billion | $6.49 Billion | 0.00x | 0.00x |
| 2023 | $824.17K | $3.40 Million | -$45.61 Million | 0.24x | N/A |
| 2024 | $571.60K | $2.29 Million | -$33.46 Million | 0.25x | N/A |
| 2025 | $313.72K | $3.00 Million | -$20.40 Million | 0.10x | N/A |
Competitor Companies of RENX by Market Capitalization
Companies near Renalytix AI plc in the global market cap rankings as of September 19, 2026. Review Renalytix AI plc (RENX) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Renalytix AI plc by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #737 globally with a market cap of $37.44 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1877 globally with a market cap of $12.53 Billion USD ( AU$17.71 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2076 globally with a market cap of $11.06 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2153 globally with a market cap of $10.63 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #737 | Veeva Systems Inc Class A | NYSE:VEEV | $37.44 Billion | $260.21 |
| #1877 | Pro Medicus Ltd | AU:PME | $12.53 Billion | AU$169.57 |
| #2076 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $11.06 Billion | $77.84 |
| #2153 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $56.78 |
Renalytix AI plc Historical Marketcap From 2018 to 2026
Between 2018 and today, Renalytix AI plc's market cap moved from $6.51 Million to $ 332.33K, with a yearly change of -31.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX332.33K | +5.93% |
| 2025 | GBX313.72K | -45.12% |
| 2024 | GBX571.60K | -30.65% |
| 2023 | GBX824.17K | -78.62% |
| 2022 | GBX3.86 Million | -88.49% |
| 2021 | GBX33.50 Million | +29.23% |
| 2020 | GBX25.92 Million | +33.93% |
| 2019 | GBX19.35 Million | +197.14% |
| 2018 | GBX6.51 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Renalytix AI plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $332.33K USD |
| MoneyControl | $332.33K USD |
| MarketWatch | $332.33K USD |
| marketcap.company | $332.33K USD |
| Reuters | $332.33K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Renalytix AI plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more